Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
J Gong, A Chehrazi-Raffle, S Reddi… - Journal for immunotherapy …, 2018 - Springer
Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a
subset of patients with metastatic gastric cancer (mGC). With the goal of identifying …
subset of patients with metastatic gastric cancer (mGC). With the goal of identifying …
Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose …
J Xu, Y Zhang, RU Jia, C Yue, L Chang, R Liu… - Clinical Cancer …, 2019 - AACR
Purpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and
apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced …
apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced …
Immunotherapy in gastric cancer
A Högner, M Moehler - Current oncology, 2022 - mdpi.com
Immune checkpoint inhibition is a new standard of targeted therapy in the treatment of
advanced or metastatic gastric cancer (GC) and is represented in various combinations with …
advanced or metastatic gastric cancer (GC) and is represented in various combinations with …
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
P Danaher, S Warren, R Lu, J Samayoa… - … for immunotherapy of …, 2018 - Springer
Abstract The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-
gene signature that measures a pre-existing but suppressed adaptive immune response …
gene signature that measures a pre-existing but suppressed adaptive immune response …
Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy
Improved understanding of the immune system and its role in cancer development and
progression has led to impressive advances in the field of cancer immunotherapy over the …
progression has led to impressive advances in the field of cancer immunotherapy over the …
The current state of molecular testing in the treatment of patients with solid tumors, 2019
The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …
years as knowledge, technology, and even standard clinical practice have evolved. Broad …
Genetic predictors of response to systemic therapy in esophagogastric cancer
The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients
derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 …
derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 …
Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial
J Lee, ST Kim, K Kim, H Lee, I Kozarewa… - Cancer discovery, 2019 - AACR
The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was
designed to classify patients with metastatic gastric cancer based on clinical sequencing …
designed to classify patients with metastatic gastric cancer based on clinical sequencing …